新诺迪斯(Novo Nordisk)在专利到期和竞争加剧之前,将Wegovy在印度的价格削减了多达37%。 Novo Nordisk slashed Wegovy’s price in India by up to 37% ahead of patent expiry and rising competition.

诺沃·诺迪斯克(Novo Nordisk)将其重量损失药物Wegovy的价格在印度削减了37%,将最低剂量的月成本降低到10 850卢比,因为它准备专利于2026年3月到期,并强化了与Eli Lilly的Mounjaro的竞争,后者的销售量激增。 Novo Nordisk cut the price of its weight-loss drug Wegovy by up to 37% in India, lowering the monthly cost of the lowest dose to 10,850 rupees, as it prepares for patent expiration in March 2026 and intensifies competition with Eli Lilly’s Mounjaro, which has surged in sales. 这项行动是扩大市场准入的更广泛战略的一部分,它遵循了与Encure Pharma的伙伴关系,尽管Novo Nordisk由于反托拉斯问题而失去了100亿美元的Metsera向Pfizer的投标。 The move, part of a broader strategy to expand market access, follows a partnership with Emcure Pharma and comes despite Novo Nordisk losing its $10 billion bid for Metsera to Pfizer due to antitrust concerns. 该公司的股份在星期二上涨了7.25%。 The company’s shares rose 7.25% on Tuesday.